This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

News

Three acquisitions in 12 months bolster PCI’s Global Position

Three acquisitions in 12 months bolster PCI’s Global Position for Speed-to-Market in Support of Clients’ Drug Development and Commercialization Needs

Fortified global reach with increased international presence – including expanded EU footprint and new localized services in Asia-Pacific and West Coast US

Continued investment in facilities and technologies across global network – enhancing site capabilities and capacities – with further investment in early phase development

PCI Pharma Services’ presence at CPhI Worldwide 2018 (October 9-11, Madrid, Spain – Stand 3F10) will highlight considerable growth and expansion, including acquisition and integration of providers in three key geographies, reaffirming our industry-leading position as a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry.

In the 12 months since CPhI 2017, we have continued to focus our strategic investment on supporting the biopharmaceutical industry with global access, matching this trend with an enhanced international presence to ensure drug development, manufacturing, packaging and supply services for the benefits of our clients and their patients in more than 100 countries across the world.

Our strategic approach and international perspective has ensured the organization is strongly placed and prepared for continued industry change. With Brexit pending for the UK and EU, and important regulatory deadlines approaching in the US and EU as well as for emerging market countries, PCI stands ready to ensure service continuity following considerable growth and strategic expansion.

Brexit investment

In October 2017, the acquisition of Millmount Healthcare in Dublin, Republic of Ireland signalled the organization’s proactive Brexit strategy, expanding its existing European footprint outside of the UK and reinforcing its commitment to the EU market.

To help mitigate Brexit risk, we have strengthened our EU presence further still. A series of site expansions and investments ensure business continuity for our global customer network in the wake of Brexit. These include a purpose-built laboratory to support EU release. We have also expanded our footprint further in Europe to service its customer base in the EU as a mitigation plan for the contingency of a no deal Brexit.

Regulatory changes – DSCSA, FMD, traceability and Serialization investment

In our market-leading global position, our strategic program of investment and expansion has continued across the global network throughout 2018. Our proactive approach has ensured that the organization is ready and compliant in advance of key regulatory implementation dates – including the US DSCSA in November 2018, the EU FMD in February 2019, and emerging market traceability deadlines.

Our Serialization and anticounterfeiting technology investment sets the industry benchmark, with more than 80 lines installed and actively supporting commercial products destined for the US, EU and other emerging markets.

International reach investment

Meanwhile, PCI has been on the acquisition trail since CPhI 2017 to complement and further enhance our services and global footprint. The Dublin acquisition of Millmount Healthcare in October 2017 was one of three that we have announced in the past 12 months, and the fourth in four years outside of the US. The other acquisitions being Pharmaceutical Packaging Professionals (PPP) in Melbourne in March 2018, providing new access to Australia and the wider Asia-Pacific region; and Sherpa Clinical Packaging in San Diego, CA in September 2018, extending our presence across the US to the West Coast. All three regions are critical hubs for the industry’s biopharmaceutical development.

Early stage development investment

We continue to invest in services to support client development and commercialization of new medicines, focusing on services and technologies that provide speed-to-market. To this end, the organization has maintained focus on and investment in early stage development including rapid services for expediting early phase clinical studies, expert formulation and drug development solutions, new capabilities for early stage manufacturing development including sterile drug deliveries, as well as advanced packaging technologies to get developmental product into study quickly.

PCI’s clients trust us to help support lifesaving medicines to patients all around the world. With the increasing pressures on the industry, clients need solutions that are nimble and flexible to address global uncertainties, equipped to provide true speed-to-market, and strategically positioned in key geographies to reach their desired markets,” commented PCI Chief Executive Officer, Salim Haffar. “PCI has a focused strategy of considerable investment in our existing global supply network – implementing advanced technologies and continued expansion of capacity, coupled with key targeted acquisitions, to provide a comprehensive solution for our clients’ needs. This includes investment in all facets of lifecycle management; helping expedite molecules into clinical study, ensuring effective transition of various clinical trial phases, successful commercial launch and reliable ongoing supply. Investment, paired with expertise and outstanding service, provides a framework for providing outstanding results.

Our impressive achievements since CPhI 2017 include increased geographical reach through acquisition, expanded site capacity, additional market-leading technologies and equipment. The key milestones include:

  • September 2018 – acquisition of Sherpa Clinical Packaging, enabling our expansion to West Coast, US
  • August 2018 – expanded Cold Chain infrastructure at North American Center of Excellence for Clinical Services with dedicated -40°C facility, Rockford, IL, US
  • July 2018 – leadership transition building on strong growth and customer focus: Salim Haffar announced as new CEO and Bill Mitchell as Executive Vice Chairman, effective September 2018
  • June 2018 – completed installation and validation of new Serialization suite at Center of Excellence for contained manufacturing, Tredegar, UK
  • April 2018 – launched new high containment packaging facility, Dublin, Republic of Ireland
  • March 2018 – announced expansion of Analytical Laboratories at Center of Excellence for contained manufacturing, Tredegar, UK
  • February 2018 – completed installation and validation of new Serialization suite, Dublin, Republic of Ireland
  • March 2018 – established Asia-Pacific HQ and strengthens position in market with acquisition of Australia-based Pharmaceutical Packaging Professionals (PPP)
  • January 2018 – newly expanded European Center of Excellence for Clinical Services completed validation and licencing and is operational, Bridgend, UK
  • November 2017 – celebrated 50th anniversary of PCI’s contract packaging services, Rockford, IL, US
  • October 2017 – announced new fully contained Xcelodose® 600S technology at Center of Excellence for contained manufacturing, Tredegar, UK
  • October 2017 – acquired Millmount Healthcare, Dublin, Republic of Ireland – expanding PCI’s packaging capabilities with an EU footprint

October 8, 2018


Three acquisitions in 12 months bolster PCI’s Global Position

Three acquisitions in 12 months bolster PCI’s Global Position for Speed-to-Market in Support of Clients’ Drug Development and Commercialization Needs... View Article

Acquisition of Sherpa Clinical Packaging Complete

Expansion of our global clinical services network continues to California PCI Pharma Services is pleased to announce the completion of... View Article

x